No black box warning on record for Lazcluze

As of the latest FDA labeling reviewed, Lazcluze (LAZERTINIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Lazcluze medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Venous Thromboembolic Events (VTE) : Prophylactic anticoagulation is recommended for the first four months of treatment. Monitor for signs and symptoms of VTE and treat as medically appropriate. Withhold LAZCLUZE and amivantamab based on severity. Once anticoagulant treatment has been initiated, resume LAZCLUZE and amivantamab at the same dose at the discretion of the he

No black box warning on record for Lazcluze

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Venous Thromboembolic Events (VTE) : Prophylactic anticoagulation is recommended for the first four months of treatment. Monitor for signs and symptoms of VTE and treat as medically appropriate. Withhold LAZCLUZE and amivantamab based on severity. Once anticoagulant treatment has been initiated, resume LAZCLUZE and amivantamab at the same dose at the discretion of the he

Lazcluze Black Box Warning

No black box warning on record for Lazcluze

Other warnings & precautions

Lazcluze Black Box Warning

No black box warning on record for Lazcluze

Other warnings & precautions